Sutro Biopharma
BMS pays $650m upfront for Eisai’s first ADC candidate for cancer
Phil Taylor
antibody-drug conjugate, Bristol-Myers Squibb, Eisai, immunogen, Oncology, partnering, Sutro Biopharma
0 Comment
X
BMS pays $650m upfront for Eisai’s first ADC candidate for cancer
https://pharmaphorum.com/news/bms-pays-650m-upfront-for-eisais-first-adc-candidate-for-cancer/